Company Encyclopedia
View More
name
Mersana Therap
MRSN.US
Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops antibody-drug conjugates (ADC) for cancer patients with unmet needs. The company develops Emi-Le (XMT-1660), a B7-H4-targeting Dolasynthen ADC candidate, which is in Phase 1 clinical trial; and XMT-2056, an Immunosynthen ADC targeting a novel human epidermal growth factor receptor 2 that is in Phase 1 clinical trial. Its preclinical products portfolio includes XMT-2068 and XMT-2175. It has strategic research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana Biosciences, LLC for the development of ADC product candidates.
1.946 T
MRSN.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking265/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE239.64%A
    • Profit Margin-211.21%E
    • Gross Margin-10.65%E
  • Growth ScoreD
    • Revenue YoY-4.76%D
    • Net Profit YoY6.08%C
    • Total Assets YoY-63.02%E
    • Net Assets YoY-5775.60%E
  • Cash ScoreD
    • Cash Flow Margin-47.35%D
    • OCF YoY-4.76%D
  • Operating ScoreD
    • Turnover0.29D
  • Debt ScoreE
    • Gearing Ratio194.98%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    12:41 ET Halper Sadeh LLC Encourages SEMR, EXAS, MRSN Shareholders to Contact the Firm to Discuss Their Rights

    Halper Sadeh LLC, an investor rights law firm, is investigating potential violations of federal securities laws and breaches of fiduciary duties in the sales of Semrush Holdings, Exact Sciences Corporation, and Mersana Therapeutics. Shareholders are encouraged to contact the firm to discuss their rights, as Halper Sadeh may seek increased consideration, additional disclosures, or other relief on their behalf. The firm operates on a contingent fee basis, representing investors globally in securities fraud and corporate misconduct cases.

    prnewswire·
    US
    EXAS
    -0.12%
    prnewswire·
    US
    EXAS
    -0.12%

    Mersana Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mersana Therapeutics, Inc. - MRSN

    Kahn Swick & Foti, LLC, led by former Louisiana Attorney General Charles C. Foti, Jr., is investigating the proposed sale of Mersana Therapeutics, Inc. to Day One Biopharmaceuticals, Inc. The investigation focuses on the adequacy of the $25 per share cash offer and potential milestone payments, totaling up to $55.25 per share. Shareholders are encouraged to contact KSF if they believe the transaction undervalues the company.

    MorningStar·
    US
    MRSN
    -1.36%
    MorningStar·
    US
    MRSN
    -1.36%

    Lifesci Capital Downgrades Mersana Therapeutics (NASDAQ:MRSN) to Hold

    Lifesci Capital downgraded Mersana Therapeutics (NASDAQ:MRSN) from a "strong-buy" to a "hold" rating. Other analysts, including Guggenheim, BTIG Research, Truist Financial, Wedbush, and William Blair, also downgraded the stock. The stock has an average rating of "Reduce" and a price target of $38.19. Mersana's shares rose to $27.92, with a market cap of $139.35 million. The company reported a quarterly loss, missing estimates. Institutional investors hold 93.92% of the stock. Mersana develops ADCs for cancer treatment and collaborates with several biotech firms.

    Market Beat·
    US
    MRSN
    -1.36%
    Market Beat·
    US
    MRSN
    -1.36%

    Guggenheim Reiterates Neutral Rating for Mersana Therapeutics (NASDAQ:MRSN)

    Guggenheim reiterated a "neutral" rating for Mersana Therapeutics (NASDAQ:MRSN). Other analysts have downgraded the stock, with Truist Financial, Wedbush, William Blair, and BTIG Research lowering their ratings. The stock has a consensus "Hold" rating and a target price of $55.55. Mersana's stock traded at $27.84, with a market cap of $138.94 million. Institutional investors hold 93.92% of the stock. Mersana develops ADCs for cancer treatment and collaborates with several biotech companies.

    Market Beat·
    US
    MRSN
    -1.36%
    Market Beat·
    US
    MRSN
    -1.36%

    Mersana Therapeutics Faces High Stakes with Potential Day One Biopharmaceuticals Merger Delays

    Mersana Therapeutics faces significant risks due to potential delays in its merger with Day One Biopharmaceuticals, set to conclude by January 2026. The complex process could lead to stock price declines, a $5.6 million termination fee, negative publicity, strained stakeholder relationships, and possible litigation. Wall Street holds a consensus rating of Hold on MRSN stock.

    Tip Ranks·
    US
    MRSN
    -1.36%
    Tip Ranks·
    US
    MRSN
    -1.36%
    © 2025 Longbridge｜Disclaimer